Zevra Therapeutics Announces Interim Data from the Phase 2 Clinical Trial of KP1077 for Idiopathic Hypersomnia
October 02, 2023 07:30 ET
|
Zevra Therapeutics
Data generated to date indicate SDX is well-tolerated across all doses and both dosing regimens studied, laying the groundwork for future Phase 3 trial Topline data from completed trial expected in...
Zevra Therapeutics to Participate in the Cantor Global Healthcare Conference
September 20, 2023 07:30 ET
|
Zevra Therapeutics
CELEBRATION, Fla., Sept. 20, 2023 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a rare disease therapeutics company, today announced that executive...
Zevra Therapeutics Presents Full Data Set on the Cardiovascular Safety and Pharmacokinetics of SDX, the sole API in KP1077, in Healthy Volunteers at Psych Congress 2023
September 09, 2023 20:00 ET
|
Zevra Therapeutics
CELEBRATION, Fla., Sept. 09, 2023 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a rare disease therapeutics company, today announced a poster presentation...
Zevra Therapeutics to Participate in the H.C. Wainwright 25th Annual Global Investment Conference
September 05, 2023 07:30 ET
|
Zevra Therapeutics
CELEBRATION, Fla., Sept. 05, 2023 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a rare disease therapeutics company, today announced that executive...
Zevra Therapeutics to Acquire Acer Therapeutics, Expanding its Rare Disease Portfolio and Adding Commercial Product
August 31, 2023 07:30 ET
|
Zevra Therapeutics; Acer Therapeutics Inc.
Proposed acquisition of Acer for $15M in Zevra stock plus Contingent Value Rights (CVRs) and Zevra’s purchase of Acer’s secured debt in capital efficient structure Zevra to assume commercialization...
Zevra Therapeutics Reports Corporate Updates and Second Quarter 2023 Financial Results
August 14, 2023 07:30 ET
|
Zevra Therapeutics
Completed collaborative and productive pre-submission meeting with FDA for arimoclomol NDA in August 2023; filing expected in Q4 2023 Net revenue of $8.5M for Q2 2023, which includes $5 million...
Zevra Therapeutics Appoints Thomas Anderson to Board of Directors and Announces Retirement of Matthew R. Plooster
August 07, 2023 16:45 ET
|
Zevra Therapeutics
CELEBRATION, Fla., Aug. 07, 2023 (GLOBE NEWSWIRE) -- Zevra Therapeutics (NasdaqGS: ZVRA) ("Zevra" or “the Company"), a rare disease company melding science, data, and patient need to create...
Zevra Therapeutics to Report Second Quarter 2023 Results on August 14, 2023
August 02, 2023 07:30 ET
|
Zevra Therapeutics
CELEBRATION, Fla., Aug. 02, 2023 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company, formerly KemPharm, Inc.), a rare disease therapeutics company, has announced...
Zevra Therapeutics to Participate in the 2023 NNPDF Family Support and Medical Conference
July 19, 2023 07:30 ET
|
Zevra Therapeutics
CELEBRATION, Fla., July 19, 2023 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company, formerly KemPharm, Inc.), a rare disease therapeutics company, today announced...
Zevra Therapeutics to be Added to Russell 2000® and Russell 3000® Indexes Effective June 26, 2023
June 20, 2023 07:30 ET
|
Zevra Therapeutics
CELEBRATION, Fla., June 20, 2023 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company, formerly KemPharm, Inc.), a rare disease therapeutics company, announced its...